Drug recall · April 2, 2025
fentaNYL Citrate PF 200 mcg/100 mL recall
Why: Lack of Assurance of Sterility
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
fentaNYL Citrate PF 200 mcg/100 mL (2 mcg/ml) /0.1% Bupivacaine HCl 100 mg/100 mL (1 mg/mL), 100 ml in NS Yellow CADD FSFF, Injection for Epidural Use (Not intended For IV Use), Compounded, For Institutional or Office Use Only, QuVa Pharma, 1075 West Park One Drive, Suite 100, Sugar Land, Tx 77478. NDC: 70092-1255-75
- Lots / codes
Lots: 10140259, 10140539, 10140687, 10140688; Exp 04/24/2025
- Quantity
- N/A
- Company
- QuVa Pharma, Inc., Sugar Land, TX
- Distribution
- U.S. Nationwide
- Initiated
- March 6, 2025 · Voluntary: Firm initiated
- Classified
- March 25, 2025
- Reported
- April 2, 2025
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Bupivacaine
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.